RXi completes Apthera acquisition
This article was originally published in Scrip
Executive Summary
RNAi pioneer RXi Pharmaceuticals has completed its previously announced acquisition of the privately held biotech company Apthera, a cancer immunotherapy developer, making Apthera a wholly owned subsidiary. The buyout gives RXi Apthera's late-stage product candidate, the experimental cancer vaccine NeuVax, which will be the merged company's lead candidate (scripintelligence.com, 1 April 2011).